Insights from 2025 ASCO® GI Annual Meeting
Video Player is loading.
10 seconds
Playback speed
ASCO® GI 2025 Insights: Neoadjuvant mFOLFIRINOX vs. Gem/nab-Paclitaxel in Borderline Resectable & Resectable Pancreatic Cancer
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Kriti Dhamija
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Kriti Dhamija
Comments 0
Login to view comments.
Click here to Login
